What is HC Wainwright's Estimate for ARQT FY2026 Earnings?

Key Points

• HC Wainwright cut its FY2026 EPS estimate for Arcutis Biotherapeutics to $0.25 from $0.44, below the analyst consensus estimate of $0.33.
• The firm also forecast EPS of $0.67 for FY2027, $1.25 for FY2028, $1.62 for FY2029, and $1.83 for FY2030.
• Arcutis reported quarterly EPS of $0.06, missing the $0.18 consensus, while revenue of $143.92 million slightly exceeded analyst expectations.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) - Equities researchers at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Arcutis Biotherapeutics in a report released on Thursday, November 5th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $0.25 for the year, down from their prior forecast of $0.44. The consensus estimate for Arcutis Biotherapeutics' current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics' Q4 2026 earnings at $0.16 EPS, Q4 2027 earnings at $0.24 EPS, FY2027 earnings at $0.67 EPS, FY2028 earnings at $1.25 EPS, FY2029 earnings at $1.62 EPS and FY2030 earnings at $1.83 EPS.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.12). The firm had revenue of $143.92 million for the quarter, compared to analyst estimates of $142.59 million. Arcutis Biotherapeutics had a return on equity of 14.18% and a net margin of 5.88%.

A number of other research firms also recently commented on ARQT. Weiss Ratings raised Arcutis Biotherapeutics from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, October 29th. Needham & Company LLC set a $40.00 price target on shares of Arcutis Biotherapeutics in a report on Thursday. Wall Street Zen lowered shares of Arcutis Biotherapeutics from a "buy" rating to a "hold" rating in a research report on Saturday. Jefferies Financial Group restated a "buy" rating and set a $39.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday, October 8th. Finally, Guggenheim upped their price objective on shares of Arcutis Biotherapeutics from $38.00 to $44.00 and gave the company a "buy" rating in a report on Monday, October 19th. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $39.75.

Arcutis Biotherapeutics Price Performance

Shares of ARQT stock opened at $25.55 on Monday. The stock's 50-day simple moving average is $27.16 and its 200-day simple moving average is $25.37. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.66 and a current ratio of 2.92. The firm has a market capitalization of $3.22 billion, a PE ratio of 121.67 and a beta of 1.66. Arcutis Biotherapeutics has a fifty-two week low of $19.30 and a fifty-two week high of $34.80.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Institutional investors have recently made changes to their positions in the company. Aberdeen Group plc boosted its holdings in Arcutis Biotherapeutics by 9.7% during the third quarter. Aberdeen Group plc now owns 1,204,900 shares of the company's stock worth $31,846,000 after buying an additional 106,489 shares in the last quarter. Allworth Financial LP grew its position in Arcutis Biotherapeutics by 158.2% during the third quarter. Allworth Financial LP now owns 2,089 shares of the company's stock valued at $55,000 after buying an additional 1,280 shares during the period. Russell Investments Group Ltd. grew its position in Arcutis Biotherapeutics by 244.6% during the third quarter. Russell Investments Group Ltd. now owns 116,225 shares of the company's stock valued at $3,072,000 after buying an additional 82,500 shares during the period. Fifth Third Bancorp grew its position in Arcutis Biotherapeutics by 6,472.7% during the third quarter. Fifth Third Bancorp now owns 23,136 shares of the company's stock valued at $611,000 after buying an additional 22,784 shares during the period. Finally, Maryland State Retirement & Pension System purchased a new position in Arcutis Biotherapeutics in the third quarter valued at $674,000.

Insider Activity at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Todd Watanabe sold 4,377 shares of the company's stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $31.86, for a total value of $139,451.22. Following the sale, the insider owned 712,826 shares in the company, valued at approximately $22,710,636.36. This represents a 0.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Patrick Burnett sold 8,300 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $26.52, for a total value of $220,116.00. Following the completion of the sale, the insider owned 119,289 shares in the company, valued at approximately $3,163,544.28. This represents a 6.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 123,932 shares of company stock valued at $3,553,077 in the last 90 days. 9.40% of the stock is currently owned by corporate insiders.

Key Stories Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis raised its 2026 sales guidance, a sign of improved commercial expectations. However, investors may be weighing whether the stronger outlook is already reflected in the stock. Article: Arcutis Biotherapeutics Raised 2026 Sales Guidance
• Positive Sentiment: The company began enrolling participants in a Phase 3 study of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the medicine’s potential market, though this remains a clinical-development catalyst. Article: Arcutis Begins Enrolling Phase 3 ZORYVE Study
• Neutral Sentiment: Arcutis granted stock options and restricted stock units to six new employees. The awards create some share dilution, but are routine hiring-related inducements and are not a major business update. Article: Arcutis Reports Inducement Grants
• Negative Sentiment: Third-quarter EPS was $0.06, below analyst expectations of roughly $0.17–$0.18. Revenue of $143.92 million narrowly topped forecasts, but the earnings miss appears to be the more immediate sentiment driver. Article: Arcutis Falls After Q3 Earnings Miss
• Negative Sentiment: HC Wainwright cut its EPS estimates for the first three quarters of 2027, including reducing its Q2 forecast from $0.19 to $0.14. The lowered projections add to concerns following the quarterly earnings shortfall.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company's portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis's lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.